---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-051640"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T07:30:54.923267+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools cuts 10% of workforce, targets $45-50M annual savings in FY2025

## Summary
- Reduction-in-force of ~10% including senior management positions eliminated after SomaLogic merger.
- Expected annualized operating expense savings of $45-$50 million in fiscal 2025, majority in H2 2024.
- Restructuring costs of $10-$11 million, including $4 million non-cash share-based vesting expenses.
- Closure of San Diego R&D facility; prioritization of R&D spend to improve operational efficiency.
- Q1 2024 earnings call scheduled for May 8, 2024 at 1:30 p.m. PDT.

## SEC filing metadata
- accession: 0001104659-24-051640
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000110465924051640/0001104659-24-051640-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000110465924051640/tm249061d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-051640
- JSON: https://secwatch.observer/filing/0001104659-24-051640.json
- Plain text: https://secwatch.observer/filing/0001104659-24-051640.txt

## Key facts
- Restructurings & Charges
  STANDARD BIOTOOLS INC. announced a restructuring with charges of Reduction-in-force of approximately 10% of total workforce, including elimination of certain senior management positions, with expected expenses of $10 million affecting total workforce (approximately 10% of its total workforce).
  - Type: restructuring
  - Charge: Reduction-in-force of approximately 10% of total workforce, including elimination of certain senior management positions, with expected expenses of $10 million
  - Affected area: total workforce
  - Headcount: approximately 10% of its total workforce
  source text: On April 25, 2024, Standard BioTools Inc. (the “Company”) announced a reduction-in-force of approximately 10% of its total workforce, including the elimination of certain senior management positions following the closing of the Company’s merger with SomaLogic, Inc., as part of an operational restructuring plan.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000110465924051640/0001104659-24-051640-index.htm
- Restructurings & Charges
  STANDARD BIOTOOLS INC. announced a restructuring with charges of Streamlined Operational Expenditures including closure of the Company's R&D facility in San Diego, reductions in SG&A expenses, and savings related to a more pr affecting R&D facility in San Diego and overall SG&A expenses.
  - Type: restructuring
  - Charge: Streamlined Operational Expenditures including closure of the Company's R&D facility in San Diego, reductions in SG&A expenses, and savings related to a more pr
  - Affected area: R&D facility in San Diego and overall SG&A expenses
  source text: Streamlined Operational Expenditures: Includes reductions in overall selling, general and administrative (SG&A) expenses, the closure of the Company’s R&D facility in San Diego, as well as savings related to a more prioritized R&D strategy.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000110465924051640/0001104659-24-051640-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.